{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:56:44Z","timestamp":1760029004645},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Emer Care"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Vilazodone hydrochloride is the first member in a new class of antidepressants called indolealkylamines and was approved for use in the United States in 2011 for major depressive disorder. It has a combined mechanism of action of a selective serotonin reuptake inhibitor and a partial agonist of serotonin 5-HT1A receptors. It has not been approved for use in the pediatric population, and toxicity from exploratory vilazodone ingestion has been rarely described to date. We describe 2 children with laboratory-confirmed vilazodone ingestions that led to significant toxicity including refractory status epilepticus in 1 patient and likely transient seizure activity in the other. Both patients required multiple doses of benzodiazepines; in the more severe case, barbiturates were added to control seizure activity. These children returned to baseline and had no prolonged neurologic complications. Pediatric experience with vilazodone is limited; however, the literature demonstrates 3 additional case reports of children experiencing seizure after vilazodone ingestion. With the 2 new cases presented here, it seems prudent to educate prescribers and families of the potential dangers of ingestion of vilazodone tablets by young children.<\/jats:p>","DOI":"10.1097\/pec.0000000000001174","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T17:09:41Z","timestamp":1496768981000},"page":"e51-e54","source":"Crossref","is-referenced-by-count":7,"title":["Seizures After Pediatric Vilazodone Ingestion"],"prefix":"10.1097","volume":"34","author":[{"given":"Jeannine","family":"Del Pizzo","sequence":"first","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elon K.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn T.","family":"Kopec","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Wenger","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Noyes","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Salzman","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred M.","family":"Henretig","sequence":"additional","affiliation":[{"name":"From the *The Children's Hospital of Philadelphia; \u2020Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; \u2021Duke University Medical Center, Durham, NC; \u00a7Seattle Children's Hospital, Seattle, WA; \u2225Einstein Medical Center, Philadelphia, PA; \u00b6Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ; #Section of Clinical Toxicology, The Children's Hospital of Philadelphia; and **The Poison Control Center, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230930","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.08m04637","article-title":"Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"70","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"bib2-20230930","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/S1092852914000169","article-title":"Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor","volume":"19","year":"2014","journal-title":"CNS Spectr"},{"key":"bib3-20230930","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.annemergmed.2012.06.020","article-title":"Recurrent seizure activity in a child after acute vilazodone ingestion","volume":"60","year":"2012","journal-title":"Ann Emerg Med"},{"key":"bib4-20230930","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/15563650.2015.1004583","article-title":"Psychotropic exposures in pediatric patients: Symptomatic iloperidone and vilazodone ingestions","volume":"53","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"bib5-20230930","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jemermed.2015.04.032","article-title":"Acute vilazodone toxicity in a pediatric patient","volume":"49","year":"2015","journal-title":"J Emerg Med"},{"key":"bib7-20230930","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/15563650.2012.678497","article-title":"Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children","volume":"50","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"key":"bib8-20230930","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jemermed.2003.06.005","article-title":"Seizure secondary to citalopram overdose","volume":"26","year":"2004","journal-title":"J Emerg Med"},{"key":"bib9-20230930","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.yebeh.2008.08.015","article-title":"Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment","volume":"14","year":"2009","journal-title":"Epilepsy Behav"},{"key":"bib10-20230930","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2146\/ajhp110374","article-title":"Vilazodone: a novel antidepressant","volume":"69","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"bib11-20230930","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2045125311409486","article-title":"Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor","volume":"1","year":"2011","journal-title":"Ther Adv Psychopharmacol"},{"key":"bib12-20230930","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4088\/JCP.10m06596","article-title":"A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder","volume":"72","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"bib13-20230930","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0b013e31822c6741","article-title":"A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder","volume":"31","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"bib14-20230930","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"bib15-20230930","first-page":"347","article-title":"Seizures associated with buspirone overdose: case report and literature review","volume":"21","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bib16-20230930","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/WNF.0b013e3182767efb","article-title":"Aripiprazole-induced seizure in a 3-year-old child: a case report and literature review","volume":"36","year":"2013","journal-title":"Clin Neuropharmacol"}],"container-title":["Pediatric Emergency Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006565-201803000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:06:51Z","timestamp":1696061211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006565-201803000-00021"}},"subtitle":["A Case Series"],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pec.0000000000001174","relation":{},"ISSN":["1535-1815","0749-5161"],"issn-type":[{"value":"1535-1815","type":"electronic"},{"value":"0749-5161","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}